Eupraxia Pharmaceuticals reports Q1 net loss $6.8M vs. $6.2M last year

The Company had cash of $27.5M as of March 31, down from $33.1M at the end of the Q4.”We recently achieved a significant clinical milestone with the release of positive nine-month data from our ongoing open-label, dose-escalation Phase 1b/2a RESOLVE trial, which continue to support EP-104GI as a potentially transformative therapy for eosinophilic esophagitis,” said James Helliwell, CEO of Eupraxia. “The sustained or improved treatment outcomes observed over a nine-month period after a single treatment with 48mg dose of EP-104GI is a promising finding in the treatment of EoE with an injectable delivery system. We believe these results provide further evidence of the precision and durability of our DiffuSphere technology and provide a strong foundation as we advance into higher-dose cohorts in the coming quarters.”